Loading clinical trials...
Loading clinical trials...
Clinical Trial for the Safety and Efficacy of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
Conditions
Interventions
Murine CD19 CAR-T cells
Locations
1
China
The First Affiliated Hospital，College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Start Date
November 1, 2020
Primary Completion Date
November 1, 2023
Completion Date
November 1, 2026
Last Updated
October 26, 2020
NCT05376111
NCT04065399
NCT05453500
NCT07295951
NCT05442515
NCT05292664
Lead Sponsor
Zhejiang University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions